問卷

TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Hematology & Oncology

Division of Ophthalmology

Division of Neurology

更新時間:2023-09-19

魏以宣
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

33Cases

2022-10-01 - 2024-12-12

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2020-09-15 - 2024-03-29

Phase III

A Phase III, Randomized, Double-blind Study to Assess the Efficacy and Safety of Lazertinib Versus Gefitinib as the First-line Treatment in Patients With Epidermal Growth Factor Receptor Sensitizing Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
  • Condition/Disease

    Epidermal Growth Factor Receptor Sensitizing Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  • Test Drug

    Lazertinib

Participate Sites
7Sites

Recruiting6Sites

Terminated1Sites

2020-07-22 - 2025-11-30

Phase III

An Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab Versus Chemotherapy Alone in Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
  • Condition/Disease

    Locally Advanced or Metastatic Urothelial Cancer

  • Test Drug

    Enfortumab vedotin

Participate Sites
7Sites

Recruiting7Sites

1 2 3 4